[Edaily Reporter Shin Ha-yeon ] GC CELL(144510)announced on the 20th that it has received approval from the Ministry of Food and Drug Safety for amendments to the domestic Phase 1 clinical trial plan for “GCC2005.”
The company is currently conducting a clinical trial to evaluate the safety and tolerability of GCC2005 in the treatment of patients with recurrent or refractory NK and T-cell malignancies.
To ensure treatment convenience for patients and identify an appropriate dosing regimen, the company plans to add a single-dose group to the dose-escalation phase and collect additional data through a backfill cohort to determine the optimal dosage and frequency for use in the Phase 2 clinical trial.
The company is currently conducting a clinical trial to evaluate the safety and tolerability of GCC2005 in the treatment of patients with recurrent or refractory NK and T-cell malignancies.
To ensure treatment convenience for patients and identify an appropriate dosing regimen, the company plans to add a single-dose group to the dose-escalation phase and collect additional data through a backfill cohort to determine the optimal dosage and frequency for use in the Phase 2 clinical trial.
